首页> 外文学位 >Adolescent 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') exposure in rats: Behavioral, neurochemical, and pharmocokinetic activity.
【24h】

Adolescent 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') exposure in rats: Behavioral, neurochemical, and pharmocokinetic activity.

机译:大鼠3,4-亚甲基二氧基甲基苯丙胺(MDMA或'摇头丸')青春期暴露:行为,神经化学和药代动力学活性。

获取原文
获取原文并翻译 | 示例

摘要

The drug +/-3,4-methylenedioxymethamphetamine (MDMA or ecstasy) is a popular recreational substance among young people. Most prior research has not attempted to carefully emulate human ecstasy use patterns in animal investigations. The objectives of the present series of experiments were to develop a rat model of intermittent ecstasy use and to begin to characterize the acute and long-term physiological, behavioral, and neurochemical consequences of adolescent MDMA exposure. In Experiments I and II, male Sprague-Dawley rats received 20 mg/kg/day of MDMA on every fifth day from postnatal day 35 to 60. This regimen caused subtle reductions in cortical serotonin transporter (SERT) binding and dose dependently modified indices of attention, working memory, and anxiety-like behavior. Experiment III tested whether periadolescent MDMA exposure (10 mg/kg x 2) modified the responses to a MDMA binge (5 or 10 mg/kg x 4) in young adulthood. Adolescent MDMA completely blocked the hypoactivity and SERT reductions induced by adult MDMA treatments. Importantly, developmental MDMA exposure only partially reduced the hyperthermia evoked by the binge. The pharmacokinetic profile of early (PD 35) and late (PD 60) adolescent MDMA (10 mg/kg) treatments were compared in Experiment IV. Pharmacokinetic parameters (elimination half-life, peak concentration) did not differ by age for MDMA but PD 60 animals showed lower peak concentrations of the metabolite methylenedioxyamphetamine (MDA). Finally, the goal of Experiment V was to determine if MDMA induced decreases in SERT levels mediated the behavioral consequences. Rats received the binge (10 mg/kg x 4) in combination with pretreatment with the serotonin reuptake inhibitor citalopram (10 mg/kg). Citalopram blocked SERT reductions measured one week after dosing and prevented some of the MDMA induced alterations in complex behavior. These studies reveal that: (1) repeated exposure to a clinically relevant MDMA dose can reduce cognitive function and alter affective behavior, (2) adolescent MDMA can lead to MDMA tolerance in adulthood, (3) the behavioral toxicology of MDMA may not be exclusively mediated by decreases in SERT. Overall, these findings indicate that the enduring neurobiological consequences of MDMA may not be limited to the serotonergic system and have substantial public health implications for regular ecstasy users.; Keywords. Adolescence, Behavior, Memory, Serotonin transporter, Temperature, Weight
机译:+/- 3,4-亚甲二氧基甲基苯丙胺(摇头丸或摇头丸)是年轻人中流行的娱乐性物质。大多数先前的研究都没有尝试在动物研究中仔细模拟人类摇头丸的使用方式。本系列实验的目的是建立间歇性摇头丸使用的大鼠模型,并开始表征青少年MDMA暴露的急性和长期生理,行为和神经化学后果。在实验I和实验II中,雄性Sprague-Dawley大鼠从出生后第35天到60天每隔第五天接受20 mg / kg /天的MDMA。该方案引起皮质5-羟色胺转运蛋白(SERT)结合的轻微降低,并且剂量依赖性地改变了注意,工作记忆和焦虑样行为。实验III测试了青春期MDMA暴露量(10 mg / kg x 2)是否能改变成年后对MDMA暴食(5或10 mg / kg x 4)的反应。青少年MDMA完全阻断了成人MDMA治疗引起的机能减退和SERT降低。重要的是,发育中的MDMA暴露仅部分减少了狂热引起的体温过高。在实验IV中比较了青春期早期(PD 35)和晚期(PD 60)MDMA(10 mg / kg)治疗的药代动力学特征。对于MDMA,药代动力学参数(消除半衰期,峰浓度)没有随年龄的变化,但PD 60动物的代谢物亚甲基二氧苯异丙胺(MDA)的峰浓度较低。最后,实验V的目标是确定MDMA是否引起SERT水平降低介导了行为后果。大鼠接受暴食(10 mg / kg x 4),并与5-羟色胺再摄取抑制剂西酞普兰(10 mg / kg)进行预处理。西酞普兰在给药后一周内阻止了SERT的降低,并阻止了某些MDMA引起的复杂行为改变。这些研究表明:(1)反复暴露于临床上相关的MDMA剂量会降低认知功能并改变情感行为;(2)青少年MDMA可能导致成年期对MDMA的耐受;(3)MDMA的行为毒理学可能并非唯一通过降低SERT介导。总体而言,这些发现表明,摇头丸的持久的神经生物学后果可能不仅限于血清素能系统,而且对常规摇头丸使用者有重大的公共卫生影响。关键字。青春期,行为,记忆力,血清素转运蛋白,温度,体重

著录项

  • 作者

    Piper, Brian James.;

  • 作者单位

    University of Massachusetts Amherst.;

  • 授予单位 University of Massachusetts Amherst.;
  • 学科 Biology Neuroscience.; Health Sciences Pharmacology.; Psychology Physiological.
  • 学位 Ph.D.
  • 年度 2007
  • 页码 172 p.
  • 总页数 172
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 神经科学;药理学;生理心理学;
  • 关键词

  • 入库时间 2022-08-17 11:40:30

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号